



Financial Tear Sheet

Stock Information

CUR (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$4.15
Change (%)	▼ 0.25 (5.68%)
Volume	54,998
52 Week Low	\$2.47
Market Cap	\$49,382,730
Rolling EPS	-2.32
PE Ratio	0
Shares Outstanding	11,899,453

Data as of 05/26/17 4:00 p.m. ET



Recent Press Releases

05/17/17

Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder

05/10/17

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update

04/12/17

Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury

03/23/17

Neuralstem Reports Year End 2016 Fiscal Results and Business Update

03/17/17

Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/24/17	8-K
05/18/17	4
05/18/17	8-K
05/12/17	8-K

Board of Directors

Richard J. Daly
Chairman

Scott V. Ogilvie
Director

William C. Oldaker
Director

Sandford D. Smith
Director

Stanley I. Westreich
Director

Management

Richard J. Daly
President and Chief Executive Officer

Dr. Karl Johe, Ph.D.
Chief Scientific Officer

Thomas G. Hazel Ph.D.
Senior Vice President, Research

Primary IR Contact

Danielle Spangler
Investor Relations
Neuralstem, Inc
Phone: 301.366.1481
E-mail: dspangler@neuralstem.com

Data Provided by Nasdaq. Minimum 15 minutes delay.